Total Payments
$139,969
2024 Payments
$992.56
Companies
14
Transactions
133
Medicare Patients
140
Medicare Billing
$20,873
Payment Breakdown by Category
Consulting$57,642 (41.2%)
Other$29,790 (21.3%)
Travel$27,622 (19.7%)
Research$22,992 (16.4%)
Food & Beverage$1,911 (1.4%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $57,642 | 19 | 41.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,790 | 20 | 21.3% |
| Travel and Lodging | $27,622 | 27 | 19.7% |
| Unspecified | $22,992 | 26 | 16.4% |
| Food and Beverage | $1,911 | 40 | 1.4% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$116,977
107 transactions
Research
$22,992
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $59,395 | 43 | $0 (2021) |
| GlaxoSmithKline, LLC. | $27,441 | 24 | $0 (2020) |
| Eli Lilly and Company | $22,565 | 26 | $0 (2020) |
| Eisai Co., Ltd. | $8,858 | 2 | $0 (2019) |
| PFIZER INC. | $5,428 | 5 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $3,836 | 8 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,630 | 1 | $0 (2021) |
| Gilead Sciences, Inc. | $3,432 | 2 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $2,600 | 4 | $0 (2019) |
| AstraZeneca UK Limited | $1,800 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $992.56 | 2 | Novartis Pharmaceuticals Corporation ($939.31) |
| 2023 | $137.52 | 1 | PFIZER INC. ($137.52) |
| 2021 | $9,514 | 8 | F. Hoffmann-La Roche AG ($5,872) |
| 2020 | $29,242 | 19 | F. Hoffmann-La Roche AG ($12,604) |
| 2019 | $44,585 | 57 | F. Hoffmann-La Roche AG ($15,083) |
| 2018 | $36,305 | 28 | F. Hoffmann-La Roche AG ($25,835) |
| 2017 | $19,193 | 18 | Eli Lilly and Company ($15,067) |
All Payment Transactions
133 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $53.25 | General |
| 07/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $939.31 | Research |
| Study: CLEE011A2301,CLEE011E2301,CLEE011F2301 • Category: Oncology | ||||||
| 11/09/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $137.52 | General |
| 06/30/2021 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $547.75 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER • Category: BioOncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/31/2021 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $2,224.76 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $1,979.34 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $294.00 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $105.83 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 03/02/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,630.00 | General |
| 02/15/2021 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $720.59 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $447.99 | Research |
| Study: Phase 3 study of Anti PDL1 with Abraxane in TN MBC • Category: BioOncology | ||||||
| 11/27/2020 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,420.00 | General |
| 11/20/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 10/01/2020 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $609.74 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $447.99 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $359.52 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $213.70 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 09/04/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: None | ||||||
| 08/25/2020 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $4,875.00 | General |
| 08/12/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $669.33 | Research |
| Study: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $545.13 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER • Category: BioOncology | ||||||
| 05/01/2020 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTI PD-L1 ANTIBODY IN COMBINATION WITH NAB PACLITAXEL COMPARED WITH PLACEBO WITH NAB PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $9,805 | 9 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE PRIMARY BREAST CANCER | F. Hoffmann-La Roche AG | $4,923 | 6 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,127 | 4 |
| CLEE011A2301,CLEE011E2301,CLEE011F2301 | Novartis Pharmaceuticals Corporation | $939.31 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $769.83 | 3 |
| Phase 3 study of Anti PDL1 with Abraxane in TN MBC | F. Hoffmann-La Roche AG | $447.99 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 69 | 116 | $49,172 | $11,342 |
| 2020 | 3 | 71 | 110 | $40,451 | $9,530 |
Total Patients
140
Total Services
226
Medicare Billing
$20,873
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 81 | $26,639 | $6,478 | 24.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 20 | $11,664 | $2,442 | 20.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $10,869 | $2,422 | 22.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 38 | 67 | $18,301 | $4,546 | 24.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $9,522 | $2,538 | 26.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 26 | $12,628 | $2,446 | 19.4% |
About Dr. Eric Winer, M.D
Dr. Eric Winer, M.D is a Medical Oncology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700854718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Winer, M.D has received a total of $139,969 in payments from pharmaceutical and medical device companies, with $992.56 received in 2024. These payments were reported across 133 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($57,642).
As a Medicare-enrolled provider, Winer has provided services to 140 Medicare beneficiaries, totaling 226 services with total Medicare billing of $20,873. Data is available for 2 years (2020–2021), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location New Haven, CT
- Active Since 03/08/2006
- Last Updated 02/04/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700854718
Products in Payments
- TECENTRIQ (Biological) $24,311
- Kadcyla (Biological) $21,721
- Halaven (Drug) $8,858
- Tecentriq (Biological) $8,168
- XTANDI (Drug) $5,290
- VERZENIO (Drug) $4,145
- KISQALI (Drug) $3,732
- Non-Covered Product (Drug) $2,782
- VYXEOS (Drug) $2,600
- Perjeta (Biological) $2,279
- BYL719 (Drug) $104.18
- ZEJULA (Drug) $23.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New Haven
Mandar Muzumdar, Md, MD
Medical Oncology — Payments: $741,000
Medical Oncology $741,000
Francine Foss, Md, MD
Medical Oncology — Payments: $280,568
Medical Oncology $280,568
Ian Krop, Md Phd, MD PHD
Medical Oncology — Payments: $256,405
Medical Oncology $256,405
Maryam Lustberg, M.d, M.D
Medical Oncology — Payments: $252,571
Medical Oncology $252,571
Lajos Pusztai, M.d., D.phil, M.D., D.PHIL
Medical Oncology — Payments: $184,479
Medical Oncology $184,479
Anne Chiang, Md, MD
Medical Oncology — Payments: $151,212
Medical Oncology $151,212